Metadata
- Name
- Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT01742988
- Description
- This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients
with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell
lymphoma (HGBL) with or without MYC and BCL2 alterations. Fimepinostat (CUDC-907) is a
multi-targeted agent designed to inhibit phosphoinositide 3-kinase (PI3K)and histone
deacetylase (HDAC). The study is designed to assess the safety, the maximum tolerated dose,
the recommended phase 2 dose (RP2D), pharmacokinetics and the anti-cancer activity of oral
fimepinostat in combination with 1 or more anti-cancer regimens. - Data or Study Types
- clinical trial
- Keywords
- Triple-hit Lymphoma (THL), HGBL, Double-expressor Lymphoma (DEL), P13K, Open-Label, Diffuse Large B-Cell Lymphoma, HDAC, MYC, Double-hit Lymphoma (DHL), Lymphoma, DLBCL, High-grade B-Cell Lymphoma
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2012
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT01742988
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT01742988